Rojo Carla, Gárate-Rascón María, Recalde Miriam, Álava Ane, Elizalde María, Azkona María, Aldabe Iratxe, Guruceaga Elisabet, López-Pascual Amaya, Latasa M Ujue, Sangro Bruno, Fernández-Barrena Maite G, Ávila Matías A, Arechederra María, Berasain Carmen
Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Bioinformatics Platform, CIMA, University of Navarra, Pamplona, Spain.
JHEP Rep. 2024 May 9;6(8):101118. doi: 10.1016/j.jhepr.2024.101118. eCollection 2024 Aug.
BACKGROUND & AIMS: The homeostasis of the cellular transcriptome depends on transcription and splicing mechanisms. Moreover, the fidelity of gene expression, essential to preserve cellular identity and function is secured by different quality control mechanisms including nonsense-mediated RNA decay (NMD). In this context, alternative splicing is coupled to NMD, and several alterations in these mechanisms leading to the accumulation of aberrant gene isoforms are known to be involved in human disease including cancer.
RNA sequencing, western blotting, qPCR and co-immunoprecipitation were performed in multiple silenced culture cell lines (replicates n ≥4), primary hepatocytes and samples of animal models (Jo2, APAP, mice, n ≥3).
Here we show that in animal models of liver injury and in human HCC (TCGA, non-tumoral = 50 . HCC = 374), the process of NMD is inhibited. Moreover, we demonstrate that the splicing factor SLU7 interacts with and preserves the levels of the NMD effector UPF1, and that SLU7 is required for correct NMD. Our previous findings demonstrated that SLU7 expression is reduced in the diseased liver, contributing to hepatocellular dedifferentiation and genome instability during disease progression. Here we build on this by providing evidence that caspases activated during liver damage are responsible for the cleavage and degradation of SLU7.
Here we identify the downregulation of UPF1 and the inhibition of NMD as a new molecular pathway contributing to the malignant reshaping of the liver transcriptome. Moreover, and importantly, we uncover caspase activation as the mechanism responsible for the downregulation of SLU7 expression during liver disease progression, which is a new link between apoptosis and hepatocarcinogenesis.
The mechanisms involved in reshaping the hepatocellular transcriptome and thereby driving the progressive loss of cell identity and function in liver disease are not completely understood. In this context, we provide evidence on the impairment of a key mRNA surveillance mechanism known as nonsense-mediated mRNA decay (NMD). Mechanistically, we uncover a novel role for the splicing factor SLU7 in the regulation of NMD, including its ability to interact and preserve the levels of the key NMD factor UPF1. Moreover, we demonstrate that the activation of caspases during liver damage mediates SLU7 and UPF1 protein degradation and NMD inhibition. Our findings identify potential new markers of liver disease progression, and SLU7 as a novel therapeutic target to prevent the functional decay of the chronically injured organ.
细胞转录组的稳态取决于转录和剪接机制。此外,基因表达的保真度对于维持细胞特性和功能至关重要,这通过包括无义介导的RNA降解(NMD)在内的不同质量控制机制得以保障。在这种情况下,可变剪接与NMD相关联,已知这些机制中的几种改变导致异常基因异构体的积累,与包括癌症在内的人类疾病有关。
在多个沉默培养细胞系(重复n≥4)、原代肝细胞和动物模型样本(Jo2、APAP、小鼠,n≥3)中进行RNA测序、蛋白质免疫印迹、定量PCR和免疫共沉淀。
我们在此表明,在肝损伤动物模型和人类肝癌(TCGA,非肿瘤=50,肝癌=374)中,NMD过程受到抑制。此外,我们证明剪接因子SLU7与NMD效应因子UPF1相互作用并维持其水平,且正确的NMD需要SLU7。我们之前的研究结果表明,在患病肝脏中SLU7表达降低,在疾病进展过程中导致肝细胞去分化和基因组不稳定。在此基础上,我们提供证据表明肝脏损伤期间激活的半胱天冬酶负责SLU7的切割和降解。
我们在此确定UPF1的下调和NMD的抑制是导致肝脏转录组恶性重塑的新分子途径。此外,重要的是,我们发现半胱天冬酶激活是肝脏疾病进展过程中SLU7表达下调的机制,这是细胞凋亡与肝癌发生之间的新联系。
重塑肝细胞转录组从而导致肝脏疾病中细胞特性和功能逐渐丧失的机制尚未完全了解。在此背景下,我们提供了关于一种关键的mRNA监测机制即无义介导的mRNA降解(NMD)受损的证据。从机制上讲,我们揭示了剪接因子SLU7在NMD调节中的新作用,包括其与关键NMD因子UPF1相互作用并维持其水平的能力。此外,我们证明肝脏损伤期间半胱天冬酶的激活介导SLU7和UPF1蛋白降解以及NMD抑制。我们的研究结果确定了肝脏疾病进展的潜在新标志物,并将SLU7作为预防慢性损伤器官功能衰退的新治疗靶点。